Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species

Rapolas Žilionis, Camilla Engblom, Christina Pfirschke et al. · Immunity · 2019 · 1.5K citations · Full text

Life Sciences, Cell Biology, Oncology +12

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba et al. · Cancer Discovery · 2011 · 893 citations

Medicine, Oncology, Pharmacology +17

<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila et al. · Cancer Discovery · 2012 · 726 citations · Full text

Medicine, Oncology, Pharmacology +17